This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall.
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -180% and 21.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Vivos Therapeutics (VVOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -13.64% and 26.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
by Ekta Bagri
BMY and VERV are in the spotlight this week following the failure of a late-stage study and positive cholesterol study data, respectively.
Ironwood Shares Tank on Regulatory Update for Apraglutide
by Zacks Equity Research
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.
Corcept (CORT) Stock Jumps 109.1%: Will It Continue to Soar?
by Zacks Equity Research
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
by Zacks Equity Research
Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -80% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls
by Zacks Equity Research
Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support.
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
by Zacks Equity Research
IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. Stock falls.
Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -77.78% and 2.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Ironwood (IRWD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ironwood (IRWD) stock based on the movements in the options market lately.
Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. The company lowers revenue guidance for 2024. Stock falls.
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of -100% and 9.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -50% and 1.91%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for July 23rd
by Zacks Equity Research
ALK, DINO and IRWD have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2024.
Implied Volatility Surging for Ironwood Pharmaceuticals (IRWD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ironwood Pharmaceuticals (IRWD) stock based on the movements in the options market lately.
New Strong Sell Stocks for July 5th
by Zacks Equity Research
ARCO, IRWD and AVT have been added to the Zacks Rank #5 (Strong Sell) List on July 5, 2024.
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Ironwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.
Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline
by Zacks Equity Research
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.